Vycor Medical, Inc. VYCO
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -8.77% | 9.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -8.77% | 9.98% | |||
| Cost of Revenue | -11.51% | 2.33% | |||
| Gross Profit | -8.21% | 11.87% | |||
| SG&A Expenses | 2.31% | -11.65% | |||
| Depreciation & Amortization | 6.43% | -6.04% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.31% | -8.98% | |||
| Operating Income | -84.93% | 225.48% | |||
| Income Before Tax | -195.02% | 132.21% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -195.02% | 132.21% | |||
| Earnings from Discontinued Operations | -- | 100.00% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -210.95% | 132.06% | |||
| EBIT | -84.93% | 225.48% | |||
| EBITDA | -65.37% | 401.47% | |||
| EPS Basic | 83.72% | -126.32% | |||
| Normalized Basic EPS | -200.00% | 133.33% | |||
| EPS Diluted | 83.72% | -126.32% | |||
| Normalized Diluted EPS | -200.00% | 133.33% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||